Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone44-20-7611-2077
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees27
OptionableNot Optionable
Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions
What is Nightstar Therapeutics' stock symbol?
Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE."
How were Nightstar Therapeutics' earnings last quarter?
Nightstar Therapeutics PLC (NASDAQ:NITE) posted its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.13. View Nightstar Therapeutics' Earnings History.
When is Nightstar Therapeutics' next earnings date?
What price target have analysts set for NITE?
9 brokers have issued 12-month price objectives for Nightstar Therapeutics' shares. Their forecasts range from $21.00 to $42.00. On average, they expect Nightstar Therapeutics' share price to reach $32.8889 in the next twelve months. This suggests a possible upside of 125.6% from the stock's current price. View Analyst Price Targets for Nightstar Therapeutics.
What is the consensus analysts' recommendation for Nightstar Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nightstar Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nightstar Therapeutics.
What are Wall Street analysts saying about Nightstar Therapeutics stock?
Here are some recent quotes from research analysts about Nightstar Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "Nightstar is developing AAV-vector-based gene therapies for ophthalmological indications. Nightstar is currently conducting a Phase 3 (STAR) study of the treatment of choroideremia. Nightstar has shown positive Phase 2 data in multiple investigator sponsor led trials in four different countries. In our view, Nightstar has a potential first mover advantage in this indication, where a large unmet medical need exists." (1/31/2019)
- 2. According to Zacks Investment Research, "Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The company operates primarily in North America and Europe. Nightstar Therapeutics Limited is based in LONDON, United Kingdom. " (1/9/2019)
- 3. Mizuho analysts commented, "We attended Nightstar’s R&D Day yesterday where management presented preliminary data from the dose escalation study of NSR-RPGR for the treatment of X-Linked Retinitis Pigmentosa. We were encouraged by early signals observed in all cohort 3 patients and 2/6 patients in cohorts 4 and 5. However, the therapeutic dose to be taken into the upcoming expansion study remains to be determined as higher dose responders required a second course of steroids to control mild sub-retinal inflammation. The next important catalyst for the shares will be 2Q19 with six-months follow-up data from the dose escalation study. We maintain our Buy rating on the stock." (9/25/2018)
Has Nightstar Therapeutics been receiving favorable news coverage?
News coverage about NITE stock has been trending somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Nightstar Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Are investors shorting Nightstar Therapeutics?
Nightstar Therapeutics saw a drop in short interest during the month of January. As of January 15th, there was short interest totalling 425,477 shares, a drop of 29.8% from the December 31st total of 606,365 shares. Based on an average daily trading volume, of 66,373 shares, the days-to-cover ratio is currently 6.4 days. Currently, 1.3% of the company's stock are sold short. View Nightstar Therapeutics' Current Options Chain.
Who are some of Nightstar Therapeutics' key competitors?
Some companies that are related to Nightstar Therapeutics include Alector (ALEC), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Iovance Biotherapeutics (IOVA), Autolus Therapeutics (AUTL), Rubius Therapeutics (RUBY), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Editas Medicine (EDIT), Fate Therapeutics (FATE), Coherus Biosciences (CHRS), Sangamo Therapeutics (SGMO), Vericel (VCEL), Novavax (NVAX) and BAVARIAN NORDIC/S (BVNRY).
Who are Nightstar Therapeutics' key executives?
Nightstar Therapeutics' management team includes the folowing people:
- Mr. David Fellows, CEO & Director (Age 62)
- Mr. Senthil Vel Sundaram, Chief Financial Officer (Age 41)
- Dr. Gregory Scott Robinson, Chief Scientific Officer (Age 60)
- Brian Luque, Sr. Mang. of Investor Relations
- Mr. Seokho Bryan Yoon Esq., Gen. Counsel & Sec. (Age 40)
When did Nightstar Therapeutics IPO?
(NITE) raised $76 million in an IPO on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.
Who are Nightstar Therapeutics' major shareholders?
Nightstar Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sectoral Asset Management Inc (0.83%), Tekla Capital Management LLC (0.35%), United Services Automobile Association (0.22%), Squarepoint Ops LLC (0.16%), Millennium Management LLC (0.13%) and Virtus ETF Advisers LLC (0.10%). Company insiders that own Nightstar Therapeutics stock include David A Fellows, Gregory Scott Robinson and Senthil Vel Sundaram. View Institutional Ownership Trends for Nightstar Therapeutics.
Which institutional investors are selling Nightstar Therapeutics stock?
NITE stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Tekla Capital Management LLC, United Services Automobile Association and Sectoral Asset Management Inc. Company insiders that have sold Nightstar Therapeutics company stock in the last year include David A Fellows, Gregory Scott Robinson and Senthil Vel Sundaram. View Insider Buying and Selling for Nightstar Therapeutics.
Which institutional investors are buying Nightstar Therapeutics stock?
How do I buy shares of Nightstar Therapeutics?
Shares of NITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nightstar Therapeutics' stock price today?
One share of NITE stock can currently be purchased for approximately $14.58.
How big of a company is Nightstar Therapeutics?
Nightstar Therapeutics has a market capitalization of $409.70 million. The company earns $-29,680,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Nightstar Therapeutics employs 27 workers across the globe.
What is Nightstar Therapeutics' official website?
How can I contact Nightstar Therapeutics?
Nightstar Therapeutics' mailing address is 215 EUSTON ROAD, LONDON X0, NW1 2BE. The company can be reached via phone at 44-20-7611-2077 or via email at [email protected]
MarketBeat Community Rating for Nightstar Therapeutics (NASDAQ NITE)
MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe NITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NITE will underperform the S&P 500 over the long term. You may vote once every thirty days.
